IPCA Laboratories logo

IPCALAB - IPCA Laboratories Share Price

₹2159.05 6.1  0.3%

Last Trade - 13/04/21

Large Cap
Market Cap £2.66bn
Enterprise Value £2.59bn
Revenue £522.1m
Position in Universe 148th / 3106
Unlock IPCALAB Revenue
Relative Strength (%)
1m +15.3%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -12.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
31,418 29,065 32,106 32,852 37,750 46,499 55,285 60,825 +8.2%
-46.6 -63.2 +108.4 +21.8 +85.7 +39.8 +89.8 -2.93
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 31 December 2020, IPCALaboratories Ltd revenues increased 20% to RS43.05B. Netincome increased 88% to RS9.79B. Revenues reflect anincrease in demand for the Company's products and servicesdue to favorable market conditions. Net income benefitedfrom Other Expenses decrease of 4% to RS8.44B (expense),Finance Cost decrease of 43% to RS73.4M (expense), EquityEarnings -Before Taxes decrease of 5% to RS52M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for IPCALAB
Graphical History


IPCALAB Revenue Unlock IPCALAB Revenue

Net Income

IPCALAB Net Income Unlock IPCALAB Revenue

Normalised EPS

IPCALAB Normalised EPS Unlock IPCALAB Revenue

PE Ratio Range

IPCALAB PE Ratio Range Unlock IPCALAB Revenue

Dividend Yield Range

IPCALAB Dividend Yield Range Unlock IPCALAB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
IPCALAB EPS Forecasts Unlock IPCALAB Revenue
Profile Summary

Ipca Laboratories Limited is engaged in pharmaceuticals business. The Company is a manufacturer and supplier of over 10 active pharmaceutical ingredients (APIs). It offers APIs, such as atenolol, hydroxychloroquine sulfate, morantel citrate, pyrantel pamoate and zaltoprofen. It offers brands, such as Zerodol, Lariago, HCQS Perinorm, Rapither, Tenoric, Lumerax, Etova, Malirid and Folitrax. Its 3c division focuses on cardiovascular and anti-diabetic markets. Its 3d division is focused on cardio-diabetic market. The Company's activa division serves the rheumatology market. Its altus division caters to the needs of intensivists, both surgical and non-surgical. Its Bionova division's focus area is dermatology. Its dynamix division focuses on cardiovascular, gastro-intestinal, anti-bacterial, pain management and respiratory sectors. It hycare division caters to the needs of cardiologists and diabetologists. Its divisions also include innova, intima, pain management, pharma and uro sciences.

Last Annual March 31st, 2020
Last Interim December 31st, 2020
Incorporated October 19, 1949
Public Since February 23, 1994
No. of Shareholders: 85,181
No. of Employees: 14,066
Sector Healthcare
Industry Pharmaceuticals
Exchange National Stock Exchange of India
Shares in Issue 126,852,109
Free Float (0.0%)
Eligible for
IPCALAB Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for IPCALAB
Upcoming Events for IPCALAB
Monday 14th June, 2021 Estimate
Full Year 2021 IPCA Laboratories Ltd Earnings Release
Monday 9th August, 2021 Estimate
Q1 2022 IPCA Laboratories Ltd Earnings Release
Friday 17th September, 2021 Estimate
Ipca Laboratories Ltd Annual Shareholders Meeting
Frequently Asked Questions for IPCA Laboratories
What is the IPCA Laboratories share price?

As of 13/04/21, shares in IPCA Laboratories are trading at ₹2159.05, giving the company a market capitalisation of £2.66bn. This share price information is delayed by 15 minutes.

How has the IPCA Laboratories share price performed this year?

Shares in IPCA Laboratories are currently trading at ₹2159.05 and the price has moved by 39.09% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the IPCA Laboratories price has moved by -12.53% over the past year.

What are the analyst and broker recommendations for IPCA Laboratories?

Of the analysts with advisory recommendations for IPCA Laboratories, there are there are currently 7 "buy" , 5 "hold" and 1 "sell" recommendations. The overall consensus recommendation for IPCA Laboratories is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will IPCA Laboratories next release its financial results?

IPCA Laboratories is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the IPCA Laboratories dividend yield?

The IPCA Laboratories dividend yield is 0.37% based on the trailing twelve month period.

Does IPCA Laboratories pay a dividend?

Last year, IPCA Laboratories paid a total dividend of 8, and it currently has a trailing dividend yield of 0.37%. Looking ahead, IPCA Laboratories has not announced an ex-dividend date yet.

When does IPCA Laboratories next pay dividends?

IPCA Laboratories has yet to annouce their ex-dividend date. The historic dividend yield on IPCA Laboratories shares is currently 0.37%.

How do I buy IPCA Laboratories shares?

To buy shares in IPCA Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of IPCA Laboratories?

Shares in IPCA Laboratories are currently trading at ₹2159.05, giving the company a market capitalisation of £2.66bn.

Where are IPCA Laboratories shares listed? Where are IPCA Laboratories shares listed?

Here are the trading details for IPCA Laboratories:

Country of listing: India
Exchange: NSI
Ticker Symbol: IPCALAB
What kind of share is IPCA Laboratories?

Based on an overall assessment of its quality, value and momentum, IPCA Laboratories is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a IPCA Laboratories share price forecast 2021?

Shares in IPCA Laboratories are currently priced at ₹2159.05. At that level they are trading at 8.12% discount to the analyst consensus target price of 0.00.

Analysts covering IPCA Laboratories currently have a consensus Earnings Per Share (EPS) forecast of 93.634 for the next financial year.

How can I tell whether the IPCA Laboratories share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IPCA Laboratories. Over the past six months, the relative strength of its shares against the market has been -15.95%. At the current price of ₹2159.05, shares in IPCA Laboratories are trading at 6.84% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the IPCA Laboratories PE Ratio?

The IPCA Laboratories PE ratio based on its reported earnings over the past 12 months is 25.64. The shares are currently trading at ₹2159.05.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of IPCA Laboratories?

IPCA Laboratories's management team is headed by:

Premchand Godha - CHM
Ajit Jain - CFO
Ashok Kumar - CEX
Anil Pareek - CEX
Anand Kusre - NID
Dev Yadava - NID
Sunil Ghai - CEX
E. Babu - CEX
Manisha Premnath - NID
Kamal Seth - NID
Pabitra Bhattacharya - CEX
Sanjay Kapadia - CEX
Goutam Muhuri - CEX
Kavita Sehwani - CEX
Who are the major shareholders of IPCA Laboratories?

Here are the top five shareholders of IPCA Laboratories based on the size of their shareholding:

Kaygee Investments Pvt. Ltd. Corporation
Percentage owned: 21.47% (27.2m shares)
Kaygee Laboratories Pvt. Ltd. Corporation
Percentage owned: 6.61% (8.39m shares)
Chandurkar Investments Pvt. Ltd. Corporation
Percentage owned: 5.5% (6.98m shares)
DSP Investment Managers Pvt. Ltd. Investment Advisor
Percentage owned: 4.07% (5.16m shares)
Paschim Chemicals Pvt. Ltd. Corporation
Percentage owned: 4% (5.07m shares)
Similar to IPCALAB
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.